

Notice of Upcoming Investor Webinar – Full Year (FY23) Results

Nova Eye Medical Limited (ASX: EYE)(**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today advises that following the release of the Appendix 4E Full Year Financial Results to 30 June 2023, the Company will host an investor webinar at 10.30am AEST (10.00am ACST, Adelaide time) on Monday, 28 August 2023 with Mr. Tom Spurling, Director of Nova Eye Medical.

Details of the webinar are set out below.

In order to pre-register for the webinar, please follow the link below.

https://us02web.zoom.us/webinar/register/WN_nw6huK1xQ6a7c3klny89uQ

Once you have registered you will be sent an email which will include a link to enter the webinar, this will give you immediate access to the event. Investors are advised to register for the conference in advance by using the link above.

This release dated 23 August 2023 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Company

Kate Hunt
Chief Commercial Officer
+61 404 080 679
khunt@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally

invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

ABOUT ALPHARET PTY LTD

AlphaRET Pty Ltd (AlphaRET) is a wholly owned subsidiary of Nova Eye Medical Limited. AlphaRET is focussed on executing the commercialization efforts for 2RT®

For additional information about AlphaRET and 2RT®, please visit: www.alpha-RET.com